Piper Sandler Issues Positive Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price

Becton, Dickinson and Company (NYSE:BDX) had its price target boosted by Piper Sandler from $175.00 to $200.00 in a research note released on Friday,Benzinga reports. Piper Sandler currently has a neutral rating on the medical instruments supplier’s stock.

Several other research firms have also recently issued reports on BDX. TD Cowen raised their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Bank of America upped their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Barclays assumed coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 target price on the stock. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Finally, Wolfe Research initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $193.67.

Becton, Dickinson and Company Price Performance

Shares of BDX traded down $1.28 during trading hours on Friday, reaching $212.27. 2,172,550 shares of the company traded hands, compared to its average volume of 1,599,485. The stock has a market capitalization of $58.49 billion, a PE ratio of 51.27, a price-to-earnings-growth ratio of 13.39 and a beta of 0.22. The stock has a fifty day simple moving average of $188.17 and a 200 day simple moving average of $170.28. Becton, Dickinson and Company has a fifty-two week low of $137.35 and a fifty-two week high of $214.88. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.08. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.11 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.96 earnings per share. As a group, research analysts predict that Becton, Dickinson and Company will post 13.24 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Thursday, November 5th that permits the company to repurchase 10,000,000 shares. This buyback authorization permits the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Share buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,907 shares of company stock worth $1,269,128. 0.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Maryland Capital Advisors Inc. grew its position in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares during the period. Trifecta Capital Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 59.0% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 62 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the last quarter. Main Street Group LTD acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth $29,000. Finally, Bell Investment Advisors Inc acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.